An Open-Label Trial of Memantine in the Treatment of Binge Eating Disorder
Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
We hypothesize that memantine may be a safe and effective treatment for moderate to severe
binge eating disorder associated with obesity.
During this 12-week, open-label, outpatient study, male and female subjects between the ages
of 18 and 65 years who have moderate to severe binge eating disorder and are obese will be
treated with open-label memantine. Following this 12-week treatment phase, subjects may be
eligible to continue into an extension phase which will last an additional 12 weeks. During
the extension phase subjects will continue open-label memantine treatment.